New York-based ZIOPHARM Oncology, Inc is a biopharmaceutical firm that specialises in acquiring, developing and commercialising cancer drugs in North America. The firm has a number of clinical programmes in progress, including developing and manufacturing Palifosfamide for use in a range of cancer treatments, Darinaparsin, an anti-mitochondrial compound for the treatment of acute promyelocytic leukemia, as well as Indibulin, a novel small molecular-weight inhibitor of tubulin polymerization. The company is also focussing on biotherapeutics that make use of DNA.
ZIOPHARM Oncology, Inc's ticker is ZIOP
The company's shares trade on the NASDAQ stock exchange
They are based in Boston, Massachusetts
There are 51-200 employees working at ZIOPHARM Oncology, Inc
It is http://www.ziopharm.com/
ZIOPHARM Oncology, Inc is in the Healthcare sector
ZIOPHARM Oncology, Inc is in the Biotechnology industry
The following five companies are ZIOPHARM Oncology, Inc's industry peers:
- Checkpoint Therapeutics, Inc.